The geometric median TCC for TNBC (63) is lower than NSCLC (93) and the corresponding response rates for the same conditional anti-PDL1 therapy are 6% and 16%, therefore higher TCC correlates with better response. The gene discussed is CD274; the disease is non-small cell lung carcinoma.